Affinity matured CD22-specific monoclonal antibody and uses thereof

US11939377B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Dimiter S. Dimitrov · Frederick, US
• Zhongyu Zhu · Frederick, US
• Sneha Ramakrishna · Bethesda, US
• Terry J. Fry · Denver, US

Key dates

• Filing date: Jul 11, 2019
• Grant date: Mar 26, 2024
• Expiry date: Jan 18, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2510/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

An affinity matured anti-CD22 human monoclonal antibody exhibiting significantly higher affinity (less than 50 pM) compared to the parental antibody (affinity of about 2 nM) is described. The anti-CD22 variant antibody or a fragment thereof, such as a single-chain variable fragment (scFv), can be used as the antigen-binding portion of chimeric antigen receptors (CARs), antibody-drug conjugates (ADCs), immunotoxins or multi-specific antibodies for the treatment of B-cell malignancies.